As newer agents for the management of metastatic colorectal cancer (mCRC) have gained approval over the past decade, they have significantly altered the treatment landscape, particularly for patients whose tumors progressed on therapy. The objective of this study was to determine the effect of online continuing medical education on the knowledge and competence of oncologists regarding evidence-based care among community oncologists.
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BACKGROUND METHODS

RESULTS
POST-ASSESSMENT
Oncologists n=185
PRE-ASSESSMENT
Oncologists n=185
The effect of 2 case-based educational interventions (5000-word interactive text based and 30-minute video based) on treatment of mCRC was analyzed to determine efficacy of online, ondemand education in these formats. The activities launched in July and December 2017 and data were collected through February 2018.
Oncologists improved in their ability to identify the most appropriate regimen for a patient with progressive mCRC
QUESTION 2 RESULTS
The majority of participating oncologists practice in the community.
Education improved oncologists' competence in using tumor characteristics to guide treatment selection Education increased oncologists' confidence in selecting the most appropriate option for a patient with progressive mCRC
QUESTION 1 RESULTS
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They are found in 80% of patients with mCRC
They are associated with an increased incidence of peritoneal and distant lymph node metastases They are associated with an increased incidence of pulmonary metastases
They are a positive predictive biomarker for EGFR antibody therapy in later lines
Oncologists improved in their ability to recognize common treatment-related adverse events and counsel patients on them
Oncologists (n = 79); P <.0001; V =.0352
Oncologists (n = 79)
Oncologists (n = 96)
Oncologists (n = 96); P =.005; V =0.2
Oncologists (n = 96); P =.107; V =0.116 Oncologists (n = 79); P <.0001; V =0.327 
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